+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hemophilia Market Size, Share & Trends Analysis Report by Type (Type A, Type B, Type C), by Treatment (On-demand, Prophylaxis), by Therapy (Replacement Therapy, Gene Therapy), by Region, and Segment Forecasts, 2020 - 2027

  • ID: 3822888
  • Report
  • March 2020
  • Region: Global
  • 90 pages
  • Grand View Research

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • BioMarin
  • CSL Behring
  • Genzyme Corporation
  • Novo Nordisk A/S
  • Octopharma AG
  • MORE
The global hemophilia market size is expected to reach USD 18.1 billion by 2027. It is anticipated to register a CAGR of 5.5% over the forecast period. Increasing awareness of early diagnosis and treatment coupled with supportive government policies is anticipated to boost market share over the forecast period.

For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.

In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.

The key market companies are projected to adopt strategic initiatives including geographic expansion and R&D especially in developing and underdeveloped regions, such as Middle Eastern and West African countries.

For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials. Furthermore, in June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi’s BIVV001 based on its preclinical study results.

Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.

Further key findings from the report suggest:
  • Hemophilia A held the largest market share in 2019 due to its increasing prevalence worldwide
  • Type B is expected to be the fastest growing type over the forecast period, at a CAGR of 6.8%
  • On-demand dominated the treatment segment over the forecast period and is expected to contribute majority of the share in 2019
  • Prophylaxis is estimated to be the fastest growing segment over the forecast period
  • Replacement therapy was expected to be the largest segment in 2019
  • Gene therapy dominated the therapy segment over the forecast period owing to increasing involvement of companies to develop more gene therapy for its treatment
  • Increasing research and development and strategic collaborations are key strategies undertaken by major players in the market space.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • BioMarin
  • CSL Behring
  • Genzyme Corporation
  • Novo Nordisk A/S
  • Octopharma AG
  • MORE
Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Information procurement
1.2.1. Purchased database
1.2.2. Internal database
1.2.3. Secondary sources & third party perspectives
1.2.4. Primary research
1.3. Information analysis
1.3.1. Data analysis models
1.4. Market formulation & data visualization
1.5. Data validation & publishing

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent/ Ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis
3.4. Regulation Framework
3.5. Market Dynamics
3.5.1. Market Driver Analysis
3.5.1.1. Increasing population of newborns
3.5.1.2. Favorable government initiative
3.5.1.3. Rising R&D and new product development
3.5.1.4. Rising adoption for prophylaxis treatment
3.5.2. Market Restraint Analysis
3.5.2.1. High cost associated to procure treatment
3.6. Hemophilia: Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power: Moderate due to presence of suppliers in the market
3.6.1.2. Buyer Power: Low due to high cost of the treatment
3.6.1.3. Substitution Threat: High due to presence of internal substitutes
3.6.1.4. Threat from new entrant: Moderate due to presence of strong global presence of existing players
3.6.1.5. Competitive rivalry: High due to involvement of companies into developing novel therapies
3.6.2. PESTEL Analysis
3.6.2.1. Political Landscape
3.6.2.2. Environmental Landscape
3.6.2.3. Social Landscape
3.6.2.4. Technology Landscape
3.6.2.5. Legal Landscape
3.6.3. Major Deals & Strategic Alliances Analysis
3.6.3.1. Joint Ventures
3.6.3.2. Mergers & Acquisitions
3.6.3.3. Licensing & Partnership
3.6.3.4. Technology Collaborations
3.6.3.5. Strategic Divestments

Chapter 4. Hemophilia Market: Segment Analysis, By Type, 2016 - 2027 (USD Million)
4.1. Definitions & Scope
4.2. Type market share analysis, 2019 & 2027
4.3. Segment Dashboard
4.4. Global Hemophilia Market, By Type, 2016 to 2027
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
4.5.1. Hemophilia A
4.5.2. Hemophilia B
4.5.3. Hemophilia C
4.5.4. Others

Chapter 5. Hemophilia market: Segment Analysis, By Treatment, 2016 - 2027 (USD Million)
5.1. Definitions & Scope
5.2. Treatment market share analysis, 2019 & 2027
5.3. Segment Dashboard
5.4. Global Hemophilia Market, By Treatment, 2016 to 2027
5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
5.5.1. On- demand
5.5.2. Prophylaxis

Chapter 6. Hemophilia market: Segment Analysis, By Therapy, 2016 - 2027 (USD Million)
6.1. Definitions & Scope
6.2. Therapy market share analysis, 2019 & 2027
6.3. Segment Dashboard
6.4. Global Hemophilia Market, By Therapy, 2016 to 2027
6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
6.5.1. Replacement therapy
6.5.2. Gene therapy
6.5.3. ITI therapy

Chapter 7. Hemophilia market: Regional Market Analysis, By Region, 2016 - 2027 (USD Million)
7.1. Definitions & Scope
7.2. Regional market share analysis, 2019 & 2027
7.3. Regional Market Dashboard
7.4. Regional Market Share and Leading Players, 2019
7.5. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East & Africa
7.6. Market Size, & Forecasts and Trend Analysis
7.7. North America
7.7.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.7.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.7.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.7.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.7.5. U.S.
7.7.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.7.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.7.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.7.6. Canada
7.7.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.7.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.7.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.8. Europe
7.8.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.8.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.8.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.8.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.8.5. Germany
7.8.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.8.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.8.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.8.6. U.K.
7.8.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.8.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.8.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.8.7. France
7.8.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.8.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.8.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.8.8. Italy
7.8.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.8.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.8.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.8.9. Spain
7.8.9.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.8.9.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.8.9.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.9. Asia Pacific
7.9.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.9.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.9.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.9.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.9.5. China
7.9.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.9.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.9.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.9.6. Japan
7.9.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.9.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.9.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.9.7. India
7.9.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.9.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.9.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.9.8. Australia
7.9.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.9.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.9.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.9.9. South Korea
7.9.9.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.9.9.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.9.9.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.10. Latin America
7.10.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.10.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.10.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.10.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.10.5. Brazil
7.10.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.10.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.10.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.10.6. Mexico
7.10.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.10.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.10.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.10.7. Argentina
7.10.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.10.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.10.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.10.8. Colombia
7.10.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.10.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.10.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.11. Middle East and Africa
7.11.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
7.11.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.11.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.11.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.11.5. South Africa
7.11.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.11.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.11.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.11.6. Saudi Arabia
7.11.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.11.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.11.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
7.11.7. UAE
7.11.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
7.11.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
7.11.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)

Chapter 8. Hemophilia market - Competitive Analysis
8.1. Recent developments & impact analysis, by key market participants
8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
8.3. Public Companies
8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
8.3.2. Company Market Share/Ranking, by region
8.3.3. Competitive Dashboard Analysis
8.4. Private Companies
8.4.1. List of key emerging companies/technology disruptors/innovators
8.4.2. Regional network map
8.4.3. Company market position analysis
8.5. Key companies profiles
8.5.1. Novo Nordisk A/S
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Shire
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Chugai Pharmaceutical Co. Ltd.
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Bayer AG
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Pfizer, Inc.
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. CSL Behring
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. BioMarin
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Octopharma AG
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Genzyme Corporation
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Spark Therapeutics, Inc.
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
Note: Product cover images may vary from those shown
  • Novo Nordisk A/S
  • Shire
  • Chugai Pharmaceutical Co. Ltd.
  • Bayer AG
  • Pfizer, Inc.
  • CSL Behring
  • BioMarin
  • Octopharma AG
  • Genzyme Corporation
  • Spark Therapeutics, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll